DISCLOSURE
This study was funded and supported by ABX Advanced Biochemical Compounds, Radeberg, Germany. Ines Rudolph and Alexander Hoepping work for ABX Advanced Biochemical Compounds. Charles Merlin has received personal fees and nonfinancial support from Curium Pharma and Novartis. Mathieu Gauthé has received personal fees and nonfinancial support from Astellas, Curium Pharma, and Novartis. The manuscript was edited for English language by Dr. Jay R Wiggins, PhD, and Dr. Kelsey L. Pomykala, MD, supported by ABX Advanced Biochemical Compounds. The ABX-CT-301 